Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics (AKRO) announced a positive End-of-Phase 2 meeting with the FDA regarding its SYNCHRONY Phase 3 clinical trials for efruxifermin (EFX) targeting nonalcoholic steatohepatitis (NASH), a severe liver disease affecting over 17 million Americans. The program includes three studies: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes, with patient enrollment expected to begin in the second half of 2023. EFX aims to demonstrate efficacy in improving fibrosis and resolving NASH, with the overall program designed for at least 1,500 patients. Akero's confidence is supported by promising results from earlier trials.
Akero Therapeutics (Nasdaq: AKRO) reported its fourth quarter and full year financial results for 2022, showcasing significant progress in developing efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH). The company highlighted the success of the HARMONY trial and EFX's Breakthrough Therapy Designation as strong indicators of its potential. For 2022, Akero's cash and equivalents totaled $351.4 million, enough to sustain operations into 2025. While R&D expenses increased to $85.3 million, administrative costs rose to $29.9 million, reflecting higher personnel costs. The company anticipates reporting results from the SYMMETRY study in 2023.
Akero Therapeutics (Nasdaq: AKRO) announced the appointment of Patrick Lamy as Senior Vice President of Commercial Strategy. Lamy, with over 25 years of experience in liver disease and commercial execution, will bolster efforts in advancing Efruxifermin (EFX), a candidate for treating NASH. Following promising results from the HARMONY study, Akero's leadership emphasized the importance of Lamy's expertise in transforming patient care for those suffering from NASH. EFX, currently in Phase 2b trials, aims to address serious metabolic conditions with significant unmet needs.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. The company's management will present their innovative treatments aimed at serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. A live webcast of the presentation will be accessible on their investor relations website, with an archived replay available afterward.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
